Anti-arrhythmic effects of SGLT2 inhibitors may be an alias for improving heart failure

Sumary of Anti-arrhythmic effects of SGLT2 inhibitors may be an alias for improving heart failure:

  • September 11, 2021 3 min read Source/Disclosures Published by: Source: Wiviott SB.
  • Disclosures: Wiviott receiv research grants from Amgen, AstraZeneca, Eisai, Merck Pfizer;
  • The TIMI study group received research grants from Abbott, Amgen, Anthos, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, The Medicines Company and Zora Biosciences.
  • ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
  • Wiviott “The pathophysiology that may causally link diabetes with atrial arrhythmias is not fully known, but has several potential mechanisms, and that includes structural changes in the heart;
  • “SGLT2 inhibitors have been shown to affect several of the things that seem to be related to diabetes and atrial fibrillation: lowering blood pressure, reducing weight and having some beneficial effects on left ventricular remodeling.
  • ” As Healio previously reported, the DECLARE-TIMI 58 trial found that dapagliflozin (Farxiga, AstraZeneca) for patients with diabetes led to a 17% lower risk for the coprimary composite efficacy endpoint of CV death or hospitalization, compared with placebo.
  • It was also observed that dapagliflozin lowered the risk for renal specific outcomes in DECLARE-TIMI 58 (HR = 0.53;

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close